comparemela.com
Home
Live Updates
Intercept Resubmits New Drug Application to U.S. FDA for Obe
Intercept Resubmits New Drug Application to U.S. FDA for Obe
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with... | December 23, 2022
Related Keywords
,
Nareg Sagherian ,
Karen Preble ,
Jerry Durso ,
Linkedin ,
Company On Twitter ,
Global Corporate Communications ,
Intercept Pharmaceuticals Inc ,
Drug Administration ,
Nasdaq ,
Globenewswire Inc ,
New Drug Application ,
Chief Executive Officer ,
Randomized Global Phase ,
Obeticholic Acid Treatment ,
Liver Fibrosis ,
Executive Director ,
Global Investor ,
Global Corporate ,
Intercept Pharmaceuticals ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
Fda ,
Upported ,
Y ,
Obust ,
Cash ,
Linical ,
Development ,
Ncluding ,
Two ,
Positive ,
Interim ,
Analyses ,
Rom ,
The ,
Hase ,
Regenerate ,
Study ,
Ncludes ,
Etailed ,
Safety ,
Analysis ,
F ,
Atients Icpt Us45845p1084 ,